Currently, there are 188.56M common shares owned by the public and among those 188.09M shares have been available to trade.
Insiders at the company have transacted a total of 12 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 12 occasions, with total insider shares sold totaling 150,037 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of 34.33% and 83.67% over the past three months. NKTR shares are trading 59.29% year to date (YTD), with the 12-month market performance down to -41.56% lower. It has a 12-month low price of $0.41 and touched a high of $1.60 over the same period. NKTR has an average intraday trading volume of 1.19 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 30.66%, 51.13%, and 53.29% respectively.
Institutional ownership of Nektar Therapeutics (NASDAQ: NKTR) shares accounts for 62.62% of the company’s 188.56M shares outstanding.
It has a market capitalization of $171.69M and a beta (3y monthly) value of 0.86. The earnings-per-share (ttm) stands at -$1.55. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.11% over the week and 11.57% over the month.
Analysts forecast that Nektar Therapeutics (NKTR) will achieve an EPS of -$0.21 for the current quarter, -$0.16 for the next quarter and -$0.76 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.33 while analysts give the company a high EPS estimate of -$0.15. Comparatively, EPS for the current quarter was -$0.32 a year ago. Earnings per share for the fiscal year are expected to increase by 6.90%, and 19.97% over the next financial year. EPS should grow at an annualized rate of -7.30% over the next five years, compared to -25.98% over the past 5-year period.
Jefferies was of a view on May 10, 2023 that the stock is Hold, while Jefferies gave the stock Underperform rating on February 24, 2023, issuing a price target of $3.20- $1.50. JP Morgan on their part issued Underweight rating on August 08, 2022.
